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Background: Methicillin-resistant Staphylococcus aureus (MRSA) infections represent a serious challenge for
health-care institutions. Rapid and precise identification of MRSA carriers can help to reduce both nosocomial
transmissions and unnecessary isolations and associated costs. The practical details of MRSA screenings (who, how,
when and where to screen) remain a controversial issue.
Methods: Aim of this study was to determine which MRSA screening and management strategy causes the lowest
expected cost for a hospital. For this cost analysis a decision analytic cost model was developed, primary based on
data from peer-reviewed literature. Single and multiplex sensitivity analyses of the parameters “costs per MRSA case
per day”, “costs for pre-emptive isolation per day”, “MRSA rate of transmission not in isolation per day” and “MRSA
prevalence” were conducted.
Results: The omission of MRSA screening was identified as the alternative with the highest risk for the hospital.
Universal MRSA screening strategies are by far more cost-intensive than targeted screening approaches. Culture
confirmation of positive PCR results in combination with pre-emptive isolation generates the lowest costs for a
hospital. This strategy minimizes the chance of false-positive results as well as the possibility of MRSA cross
transmissions and therefore contains the costs for the hospital. These results were confirmed by multiplex and
single sensitivity analyses. Single sensitivity analyses have shown that the parameters “MRSA prevalence” and the
“rate of MRSA of transmission per day of non-isolated patients” exert the greatest influence on the choice of the
favorite screening strategy.
Conclusions: It was shown that universal MRSA screening strategies are far more cost-intensive than the targeted
screening approaches. In addition, it was demonstrated that all targeted screening strategies produce lower costs
than not performing a screening at all.Background
Methicillin-resistant Staphylococcus aureus (MRSA) infec-
tions represent a serious challenge for health care institu-
tions [1-3]. In order to assure rapid treatment of MRSA
patients, a reduction of unnecessary isolation precautions
and prevention of potential cross infections as well as rapid
and precise identification of MRSA are required. Although
the implementation of MRSA screening is associated with
high expenses for the hospital, the cost-effectiveness of per-
forming MRSA screening has already been confirmed in
several studies [4-7]. However, MRSA screenings remains a
controversial issue, as the identification of the strategy* Correspondence: claudia.huebner@uni-greifswald.de
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distribution, and reproduction in any mediumwhich causes the lowest expected cost for a hospital is still
the object of inquiry.Who
Which patient groups should be included in the screening
program? A mandatory universal screening program
includes all inpatients being admitted to the hospital.
Targeted screening is limited to high-risk patients or areas
of the hospital. Among these high-risk admissions are old
and multi morbid patients, patients with chronic diseases,
open wounds, eczema, burns, and patients requiring dialy-
sis. Further documented risk factors are long hospital
stays, intravenous drug use, invasive lines or tubes such as
catheters, and prior antibiotic exposure [8,9]. The Robert
Koch-Institute defines the following patient groups as
high-risk patients: patients with nursing care dependency,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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patients with chronic wounds, burns, skin ulcers, gangrene
soft tissue infection as well as patients with known MRSA
anamnesis [8,9]. In addition to the criteria named above,
patients transferred from regions, hospitals and other
medical institutions with a noted high MRSA prevalence,
patients with a stay at another hospital during the last
three months as well as patients working in animal breed-
ing belong to the high-risk patient group. Furthermore
certain areas of the hospital are declared as high-risk areas
such as ICU, weaning ward, stroke unit and dermato-
logical ward.
How
Which laboratory technique allows a rapid, precise and
cost-effective diagnostic investigation? After swabs are
taken from the patient, hospitals can settle for the poly-
merase chain reaction (PCR) method, which is a geno-
typic method to determine the methicillin-resistance of
staphylococcus. Another option is the conventional cultur-
ing technique. Microorganisms are incubated on culture
media and are differentiated phenotypically. Susceptibility
to antimicrobials is determined afterwards by standardized
methods. Hospitals can also decide for a combination of
the two methods.
Another question that needs to be answered is how to
deal with screened patients until the MRSA test result is
available, that is, should screened patients be treated as
MRSA carriers and put in isolation until MRSA is
excluded or should no action be taken until MRSA has
been confirmed?
Where
Which swab site or rather a combination of swab sites
offers high sensitivity? Nasal swabs are considered to be
the minimum standard. Groin, axilla or wound swabs
are also appropriate [10].
When
Is it reasonable to screen patients only upon hospital
admission or to additionally conduct follow-ups and
contact-patient screenings?
The aim of this study was a cost analysis to determine
which MRSA screening and management strategy causes
the lowest expected cost for a hospital. For this purpose,
a decision tree was modelled and corresponding calcula-
tions were made. We conducted various sensitivity ana-
lyses in order to examine the stability of the results
obtained.
Methods
Decision making problem and decision tree
The decision-making process regarding the selection of
a suitable screening strategy has a complex structure. Anumber of sub-decisions lead to different alternatives.
The first branch in the decision tree results from the
basic options to screen or not to screen. Following the
branch pro-screening, it has to be clarified which patient
groups should be included in the screening program.
Should a universal screening of all inpatients be con-
ducted or a targeted screening program limited to high-
risk admissions or areas of the hospital? Hospitals can
choose the PCR methods or culture techniques, or a
combination of the two methods. If the institution has
chosen the last option, it must be determined next
whether both tests should be conducted at the same
time or if the culture test should only be applied after a
PCR test has yielded a positive result, in order to exclude
a false-positive result. The last question that must be
answered is how to deal with screened patients until the
MRSA test result is available (pre-emptive isolation or
not). Out of these different options in the decision-making
process, 19 alternative strategies arise. Each strategy is
represented by an uppercase letter, A-T (Figure 1).
Assumptions
A positive screening result is always interpreted as true
MRSA, although at first it remains unknown whether the
test is true-positive or false-negative. For this reason, isola-
tion precautions, hygiene, and MRSA eradication mea-
sures must be initiated immediately, which is in keeping
with the recommendations of the Robert Koch-Institute
[11]. In the present analysis, taking these steps in the event
of a positive test result is therefore not regarded as an
elective action but as obligatory (Figure 2). Furthermore, it
is assumed that screening contact patients is only neces-
sary if no pre-emptive isolation of the MRSA patient was
conducted until the test result was available.
If the MRSA-test is negative, pre-emptive isolation is im-
mediately discontinued and no further steps are taken. In
the present model, the decision tree branches end after
MRSA is excluded or after MRSA eradication treatment
and follow-up screening has been conducted. It is assumed
that the culture method is applied for the follow-up
screening as well as the contact-patient screening and that
these test results turn out to be negative. Therefore, costs
for a negative culture test are assessed in the calculations.
With regard to MRSA prevalence, an interrelation be-
tween the parameters “MRSA prevalence inpatients” and
“MRSA prevalence high-risk inpatients” is implied. The
higher the prevalence among all inpatients, the higher will
also be the prevalence among high-risk inpatients and vice
versa. However, the exact ratio between the two para-
meters is unknown.
Systematic literature search
Several variables (Table 1) and constants (Table 2) are
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Figure 1 Decision tree.
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selection of a specific MRSA screening strategy. In order to
obtain concrete values and significances of these factors a
systematic literature search for peer-reviewed publications
was conducted. The electronic databases PubMed and
Web of Science were searched systematically for studies
published in German and English between 1995 and April
2011. Searches were also done manually with reference lists
from these papers. The process of data acquisition isTest result + 
false +
right +
Figure 2 Measures to be taken in case of an MRSA-positive test resuldescribed in much more detail in a paper that has been
published recently [12].
The literature search resulted in 98 studies, which met
all inclusion and exclusion criteria. Of the 98 eligible
studies the following number of articles was retrieved
for each parameter:
 performance of PCR methods: 36
 performance of culture methods: 30MRSA +
MRSA -, but  
assumption
MRSA+
Measures to be taken:
Isolation,hygiene measures,   
MRSA eradication therapy 





Table 1 Definition and quantification of variables
Variable Description Average value Min value Max value References
Pt MRSA prevalence of all inpatients 3.08% 1.20% 5.30% [12]
Pr MRSA prevalence of high-risk inpatients 11.94% 3.85% 20.6% [12]
Pn.i. MRSA prevalence of patients without indication for a targeted screening 0.03% 0.03% 0.03% [13]
RTno iso Rate of MRSA transmission not in isolation per day 0.029 0.0014 0.1400 [12]
RTiso Rate of MRSA transmission in isolation per day 0.003 0.0008 0.0090 [12]
SenPCR Sensitivity of PCR method 91.09% 62.50% 100% [12]
Sencul Sensitivity of culture method 88.73% 53.00% 100% [12]
SPPCR Specificity of PCR method 95.79% 83.70% 100% [12]
SPcul Specificity of culture method 93.23% 68.00% 100% [12]
Cp iso Average costs for pre-emptive isolation per day 62.77 € 9.45 € 145.11 € [12]
CMRSA Average costs per MRSA case per day 506.92 € 213.51 € 1,411.44 € [12]
; LOSMRSA Average length of stay of MRSA patients in days 24.88 18 39 [12]
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 MRSA prevalence in German hospitals: 6
 MRSA prevalence of high-risk inpatients or patients
in high-risk areas in German hospitals: 3
 costs per MRSA case: 11
 costs for pre-emptive isolation per day: 5
As 9 of all 98 identified studies provide information
for more than one parameter of interest, these studies
were retrieved several times. Eventually, 87 different stud-
ies were identified by the search. Relevant data were
abstracted from all these studies. Tables 1 and 2 provide
an overview (minimum, maximum and average values of
the retrieved data) of the concrete values and significancesTable 2 Definition and quantification of constants
Constant Description Va
TPCR turn-around time of PCR method in days 0.2
Tcul turn-around time of culture method in days 2.5
CPCR costs for a single PCR test 20.
Ccul pos costs for a single culture test with positive result 24.
Ccul neg costs for a single culture test with negative result 6.4
Cf costs for follow-up screening 6.4
Cc costs for screening a contact patient 6.4
Patc number of contact patients 2
; LOSreg average length of stay of regular patients in days 8
Patt number of total inpatients per year 35,
Patr number of high-risk patients per year 4,3
Patn.i. number of patients without indication for a targeted
screening per year
30,
CMRSA ici costs for MRSA caused by incomplete MRSA carrier
identificationof the variables and constants obtained by the literature
review.
Parameters
Since not all parameters compiled in the Tables 1 and 2
could be quantified by systematic literature, assumptions
had to be made. The costs for a PCR test as well as for
positive and negative culture tests were estimated corre-
sponding to the German uniform valuation standard
(EBM) [14]. Estimations of the turn-around times of both
methods are based on in-house data. The number of con-
tact patients was calculated by dividing the average occu-






0 € As follow-up screening in the majority of cases leads to a
negative result, costs for negative culture tests are assessed
0 € As follow-up screening in the majority of cases leads to a
negative result, costs for negative culture tests are assessed
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The decision model calculates the expected costs for
each scenario, E(X). This principle is demonstrated by
the formula for the strategy D.
E Dð Þ ¼
Patt :Pt :Sencul
:Ccul pos þ Tcul:RTno iso:CMRSA:;LOSMRSA
þCc:Patc þþ ;LOSMRSA  Tculð Þ
:RTiso:CMRSA:;LOSMRSA
þCMRSA:;LOSMRSA þ
Patt: 1 Ptð Þ: 1 SPculð Þ½ :Ccul pos þ Cc:Patc þ Cf þ
CMRSA:;LOSreg þ
Patt: 1 Ptð Þ:SPcul½ :Ccul neg þ
Patt:Pt : 1 Senculð Þ½ :Ccul neg þ
;LOSMRSA:RTno iso:CMRSA:;LOSMRSA
Congruent to the procedure shown above, the expected
costs for each Strategy A- T are determined.
Sensitivity analyses
A multiplex sensitivity analysis was conducted by a sim-
ultaneous variation of more than one parameter. The
following variables were varied in three steps from mini-
mum to maximum of the existing data (Table 1): rate of
MRSA transmission not in isolation per day, rate of
MRSA transmission in isolation per day, costs for MRSA
case per day, costs for pre-emptive isolation per day,
MRSA prevalence inpatients, MRSA prevalence high-
risk inpatients, sensitivity of PCR method, specificity of
PCR method, sensitivity of culture method and specifi-
city of culture method. Consequentially, 59,049 (= 310)
different scenarios were generated.
Single sensitivity analyses aimed at determining the in-
fluence of a certain parameter on the expected costs of
the screening strategies. The parameter in focus was
therefore increased in ten steps from minimum to max-
imum of the existing data according to Table 1 while all
other variables were kept at their average value.
Results
Basic analysis
As presented in Figure 3 targeted screening strategies
show the lowest expected costs. Among these strategies,
a combination of PCR and culture method or perform-
ing the MRSA test via PCR is advantageous in compari-
son to the application of the culture method alone.
Strategy S, representing a targeted PCR screening and
culture confirmation in the case of a positive PCR result
and no pre-emptive isolation causes the lowest expected
costs. This approach is closely followed by Strategy R,
which also uses a targeted PCR screening with culture
confirmation in the case of a positive PCR result, but
carries out pre-emptive isolation precautions. Among alltargeted strategies, the most expensive approach is the im-
plementation of PCR and the culture method at the same
time and performing pre-emptive isolation of screened
patients until both test results are available.
The results show that an omission of an MRSA screen-
ing causes higher costs than performing a targeted screen-
ing. Only a universal screening approach is more costly
than not to perform a screening at all.
Multiplex sensitivity analysis
An analysis was performed to determine in how many of
the 59,049 scenarios the respective strategies produced
the lowest costs. The results are presented in Figure 4.
In 20,660 cases, Strategy T (no screening) causes the
lowest costs. In 12,367 scenarios, Strategy K (targeted
screening by PCR method and pre-emptive isolation)
leads to the lowest expected costs. In 7,086 out of
59,049 cases Strategy R (targeted PCR screening with
culture confirmation in the case of a positive PCR result
and pre-emptive isolation) is the best alternative. In
agreement with the results of the basic analysis, targeted
screening strategies are more cost-saving than the uni-
versal screening strategies, since they more often caused
the lowest costs.
In addition, an analysis was performed to determine in
how many cases the respective strategies cause the highest
expected costs (Figure 5). With an absolute frequency of
32,224 scenarios, Strategy F (universal screening by simul-
taneously conducting PCR and the culture method and
performing pre-emptive isolation precautions until both
results are available) most frequently shows the highest
expected costs compared to all other alternatives, which
corresponds to the results of the basic analysis. Not to per-
form an MRSA screening (Strategy T) is the second-worst
choice the decision-maker can take, followed by the uni-
versal strategies D, A and B. All other alternatives show a
low frequency of causing the highest expected costs.
Single sensitivity analysis
As expected, the increase of the parameter “costs per
MRSA case per day” led to growing costs. Over the en-
tire augmentation of this parameter strategies R and S
(targeted PCR screening with culture confirmation in
the case of a positive PCR result with and without pre-
emptive isolation) proved to be the cost-minimizing
screening strategies. These strategies showed almost
equal outcomes. However, Strategy S was favourable at
amounts up to 740 €, while Strategy R became advanta-
geous when costs per MRSA case per day were higher.
The increase of the parameter “costs for pre-emptive
isolation per day” resulted in an increase of costs for all
strategies which include the conduction of pre-emptive
isolation precautions, while the costs for all other alter-




























Figure 3 Basic analysis: Expected costs for strategies.
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to 44 €, Strategy R was the better choice. If the costs for
pre-emptive isolation per day were higher than that, the
decision-maker should choose Strategy S.
A continuous increase of the parameter “MRSA rate of
transmission not in isolation per day” also resulted in ris-
ing costs for all examined strategies. It was evident that
the costs of the alternatives which pursue pre-emptive iso-
lation precautions showed a minor increase compared the
other strategies (Figure 6). The greatest increase in costs is
observed for Strategy T (no screening). Although cost-
minimizing at a low rate of MRSA transmission, this ap-
proach became more and more expensive in the course of
parameter increase. Up to a transmission rate of 0.0154,
not performing a screening produced the lowest costs.
From this rate on to 0.042, Strategy S (targeted PCRscreening with culture confirmation in the case of a posi-
tive PCR result and no pre-emptive isolation) proved to be
the best choice. If the rate of transmission ranged from
0.042 to 0.0815, performing a targeted PCR screening and
a culture confirmation if needed as well as pre-emptive
isolation precautions (Strategy R) was the most favourable
option. If the transmission rate was higher than that, Strat-
egy K (PCR screening with pre-emptive isolation) caused
the lowest costs for the hospital.
The parameters “MRSA prevalence inpatients” and
“MRSA prevalence high-risk inpatients” were increased
separately in ten steps. Taking into account the interrelation
of these parameters, the effects are illustrated in only one
diagram (Figure 7). Increasing MRSA prevalence (all inpati-
ents and high-risk inpatients) leads to higher costs for all
strategies. In comparison to the targeted screening
486
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n = 59,049 In none of these scenarios did the Strategies E, F and P cause the lowest costs 
Figure 4 Multiple sensitivity analysis: Absolute frequency of causing the lowest costs.
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http://www.biomedcentral.com/1472-6963/12/438approaches, the universal screening strategies produce
higher costs without exception. At a low MRSA preva-
lence, Strategy T (no screening) produces costs compar-
able to the targeted screening strategies. Costs for this
alternative become disproportionately high when MRSA
prevalence increases. Once again, Strategies S and R

























n = 59,049 In none of these scenarios did the Strategies C
Figure 5 Multiple sensitivity analysis: Frequency of causing the higheprevalence of 16.9% among high-risk inpatients, Strat-
egy S (targeted PCR screening with culture confirm-
ation in the case of a positive PCR result and no pre-
emptive isolation) is the cheaper alternative. If the
MRSA prevalence among high-risk inpatients is higher
than that, choosing the same approach but performing
pre-emptive isolation is recommended (Strategy R).60 11 208 51 139
9,154
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Figure 6 Single sensitivity analysis: Rate of MRSA transmission not in isolation per day.
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To the authors’ knowledge, this study is the first quanti-
tative evaluation to determine which MRSA screening
and management strategy causes the lowest expected
cost for a hospital based on a decision-tree model. We
succeeded in identifying who, how, when and where to
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Figure 7 Single sensitivity analysis: MRSA prevalence inpatients and MThe results of the decision-tree analysis suggest that a
universal screening approach cannot be expected to be
cost-minimizing. All screening strategies pursuing a
screening for all inpatients produce higher costs than
not to perform a screening at all. This is congruent with
the results of other studies, which state that screening
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proach is neither affordable nor cost-reducing for hospi-
tals [16,17].
Furthermore, it was shown that all strategies perform-
ing a targeted screening produce lower costs in compari-
son to an omission of MRSA screening. For this reason,
evidence for the advantageousness of conducting a tar-
geted screening for all high-risk patients is provided by
cost-analyses. This is consistent with results of other
analyses [4-7,18].
Choosing Strategy T, which means not performing a
screening, implies the highest risk for the hospital.
Under certain circumstances it can be advantageous, but
oftentimes it is the most expensive alternative and on
average considerably worse than pursuing a targeted
screening approach. Risk-averse decision-makers would
therefore tend not to choose this option.
The results show that the alternatives S and R produce
the lowest expected costs among all screening strategies.
Both strategies focus on PCR screening with culture
confirmation in the case of a positive PCR result. The
difference between the two options refers to pre-emptive
isolation, which is performed by Strategy R and omitted
by Strategy S. While both alternatives on average cause
costs in similar amounts, the decision-maker should se-
lect Strategy R, because it is often the cheapest but never
the most expensive. The advantage can be ascribed to
the pre-emptive isolation precautions, which minimizes
the risk of MRSA cross transmissions and at the same
time contains the costs for the hospital. This increases
in relevance when the rate of MRSA transmission not in
isolation and MRSA prevalence turn out to be high. This
approach is also supported by the literature. When a PCR
result proves to be positive, the possibility remains that it is
false-positive, because the validity of the PCR method is
restricted in the case of a coincidental colonization with
Staphylococcus aureus and coagulase-negative staphylococ-
cus [16]. Furthermore, the PCR method can lead to posi-
tive test results even when MRSA germs have been
inactivated by a successful eradication therapy [19]. For this
reason, it is recommended to perform a culture confirm-
ation, in order to exclude false-positive PCR results [20].
Our analysis has various limitations. First, a weakness
can be seen in the quantification of the parameters
included in the calculations. Our data were basically
obtained by a systematic literature research [12], but in
some cases, the data were insufficient and assumptions
had to be made on the basis of in-house data and experi-
ence. The better the data are tailored to the particular
hospital setting, the more significant are the results pro-
duced by the decision-tree analysis modelled for this
study. In this context, a concrete limitation is evident in
terms of the single sensitivity analysis of MRSA preva-
lence. It is known that there is an interdependence ofthe parameters “MRSA prevalence”, “MRSA prevalence
high-risk inpatients” and “MRSA prevalence among
patients without indication for a targeted screening”, but
the exact ratio remains uncertain, which limits the valid-
ity of this single sensitivity analysis [13].
The results of our decision-tree analysis and the corre-
sponding calculations still allow us to draw conclusions
and give recommendations on how to perform an MRSA
screening in the cost-minimizing way.Conclusions
In summary, it was shown that universal MRSA screening
strategies are far more cost-intensive than the targeted
screening approaches. In addition, it was demonstrated
that all targeted screening strategies produce lower costs
than not performing a screening at all. The advantageous-
ness of performing a targeted MRSA screening is therefore
proven by the present analysis. The omission of an MRSA
screening was identified as the alternative attended by the
highest risk for a hospital. Among the targeted screening
strategies, performing a PCR screening and culture con-
firmation in the case of a positive PCR result (strategies R
and S) generates the lowest costs for a hospital. The
decision-maker should select Strategy R, as pre-emptive
isolation minimizes the chance of false-positive results as
well as the possibility of MRSA cross transmissions, and at
the same time contains the costs for the hospital. There-
fore, it bears a lower risk in comparison to Strategy S,
which does not take pre-emptive isolation precautions.
Further evidence, especially empiric data on costs and
outcomes, would help to strengthen the model and sup-
port the hitherto largely theoretical statements.
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